Iber-KDd

Phase 2, Single-Arm Study of Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

What's the purpose of the trial?

The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments.

Trial status

Accepting patients

Phase
Phase 2
Enrollment
30
Last Updated
4 months ago
Am I Eligible

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Acetaminophen
  • Carfilzomib
  • Daratumumab
  • Dexamethasone
  • Diphenhydramine
  • Iberdomide
  • Montelukast

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Iberdomide + Carfilzomib + Daratumumab + Dexamethasone

Accepting patients

Iberdomide

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.